Transfer of a Multiclass Method for over 60 Antibiotics in Food from High Resolution to Low Resolution Mass Spectrometry

Danilo Giusepponi 1, Fabiola Paoletti 1, Carolina Barola 1, Simone Moretti 1, Giorgio Saluti 1, Federica Ianni 2, Roccaldo Sardella 2, and Roberta Galarini 1,*

1 Istituto Zooprofilattico Sperimentale dell’Umbria e delle Marche “Togo Rosati”, 06126 Perugia, Italy
2 Department of Pharmaceutical Sciences, University of Perugia, 06123 Perugia, Italy
* Correspondence: r.galarini@izsum.it; Tel.: +39-075-343-272

Academic Editors: Alessandra Gentili and Chiara Fanali
Received: 21 July 2019; Accepted: 10 August 2019; Published: 13 August 2019

Abstract: A multiclass method has been developed to screen and confirm a wide range of anti-microbial residues in muscle and milk, and validated using liquid-chromatography coupled to (low-resolution, LR) tandem mass spectrometry (LC-QqQ). Over sixty antibiotics, belonging to ten distinct families, were included in the method scope. The development process was rapidly concluded as a result of two previously implemented methods. This consisted of identical sample treatments, followed by liquid chromatography, and coupled with high-resolution (HR) mass spectrometry (LC-Q-Orbitrap). The validation study was performed in the range between 10–1500 µg·kg⁻¹ for muscles and 2–333 µg·kg⁻¹ for milk. The main performance characteristics were estimated and, then, compared to those previously obtained with HR technique. The validity of the method transfer was ascertained also through inter-laboratory studies.

Keywords: antibiotics; liquid chromatography mass spectrometry; milk; muscle; validation

1. Introduction

Antibiotics are widely used in livestock breeding to treat several diseases that appear in all the food producing animal species. To guarantee public health protection, the European Union requires member states to implement yearly monitoring plans to control the presence of antibiotic residues in food. Therefore, surveillance should be aimed particularly at controlling compliance with the maximum residue limits (MRLs), fixed in Table 1 of the Annex of Regulation (EC) No 37/2010 [1]. For several antibiotics, MRLs have been set in various matrices, such as eggs, fat, honey, kidney, liver, milk, and muscles and still, today, new MRLs are being fixed. In the early 2000s, the liquid chromatography coupled to tandem mass spectrometry technique (LC-QqQ) became essential in the routine analysis of single class of veterinary drug residues in food. Indeed triple quadrupole mass spectrometry analyzers were able to assure both greater sensitivity and selectivity than the traditional LC detectors, based on UV-Vis and fluorescence spectroscopy. In addition, for some important classes, such as aminoglycosides or avermectins, the need of a derivation step could be avoided. In the last ten years, the improvement of LC-QqQ systems allowed the realization of a further step in drug residue analysis, introducing procedures that are able to determine simultaneously more than one drug class [2–4]. As consequence, a remarkable effort has been made to progressively replace single-class with multiclass protocols, since this is a cost-effective way to improve the current residue control programs, thereby ensuring the determination of a wide number of compounds, with only few methods. Reviewing the main relevant published papers, some research groups recurred (Table 1). Among the control laboratories, the Official Food Control Authority of Zurich (Zurich, Switzerland), the RIKILT (Wageningen, Netherlands), the
European Union Reference Laboratory for Antimicrobial Residues in Food (EURL, Fougères, France), the National Institute for Agrarian and Veterinary Research (INIAV, Vila do Conde, Portugal), the Istituto Zooprofilattico Sperimentale dell’Umbria e delle Marche (IZSUM, Perugia, Italy), the Canadian Food Inspection Agency (Calgary, Canada), the Residue Analysis Laboratory of Laboratório Nacional Agropecuário (LANAGRO, Porto Alegre, Brazil), and the US Department of Agriculture (USDA, Wyndmoor, PA, USA) are mentioning.
Table 1. Overview of multiclass methods for the determination of veterinary drug residues in tissues and milk.

| N° of Veterinary Drugs | Matrix           | Equipment                  | Reference                                        | Laboratory/Centre |
|------------------------|------------------|----------------------------|--------------------------------------------------|-------------------|
| 1                      | 18 Milk          | LC-QqQ                    | Aguilera-Luiz et al. 2008 [5]                    | Almeria University (Spain) |
| 2                      | 39 Chicken muscle | LC-QqQ                    | Chico et al. 2008 [6]                            | Barcelona University (Spain) |
| 3                      | >100 Muscle       | LC-TOF                    | Kaufmann et al. 2008 [7]                         | OFCA-Zurich (Switzerland)  |
| 4                      | >100 Milk         | LC-TOF                    | Stolker et al. 2008 [8]                          | RIKILT (The Netherlands)  |
| 5                      | Ca 100 Meat and other food | LC-TOF | Peters et al. 2009 [9]                           | RIKILT (The Netherlands)  |
| 6                      | Ca 26 Animal tissues | LC-QqQ                  | Stubbings et al. 2009 [10]                       | FERA (UK)          |
| 7                      | 58 Milk           | LC-QqQ                    | Gaugain-Juhel et al. 2009 [11]                   | EURL (France)      |
| 8                      | 21 Milk           | LC-QqQ                    | Martinez-Vidal et al. 2010 [12]                  | Almeria University (Spain) |
| 9                      | 30 Milk           | LC-Orbitrap, LC-Q-TOF, LC-QqQ | Romero-Gonzalez et al. 2011 [5]                | Almeria University (Spain) |
| 10                     | >100 Meat and other food | LC-Orbitrap       | Kaufmann et al. 2011 [13]                        | OFCA-Zurich (Switzerland) |
| 11                     | >60 Meat          | LC-LTQ-Orbitrap           | Hurtaud-Pessel et al. 2011 [14]                  | EURL (France)      |
| 12                     | 59 Milk and honey | LC-Q-TOF                  | Wang et al. 2012 [15]                            | CFIA-Calgary (Canada) |
| 13                     | 21 Meat           | LC-QqQ                    | Bittencourt et al. 2012 [16]                     | LANAGRO (Brazil)    |
| 14                     | 24 Milk and liver | LC-QqQ                    | Martins et al. 2014 [17]                         | LANAGRO (Brazil)    |
| 15                     | >100 Milk         | LC-Q-Orbitrap             | Kaufmann et al. 2014 [18]                        | OFCA-Zurich (Switzerland) |
| 16                     | 39 Liver          | LC-QqQ                    | Freitas et al. 2015 [19]                         | INIAV (Portugal)    |
| 17                     | 23 Liver          | LC-QqQ                    | Martins et al. 2015 [20]                         | LANAGRO (Brazil)    |
| 18                     | >100 Milk         | LC-Orbitrap               | Wang et al. 2015 [21]                            | CFIA-Calgary (Canada) |
| 19                     | >100 Various food | LC-Q-TOF                  | Dasenaki et al. 2015 [22]                        | University of Athens (Greece) |
| 20                     | 76 Bovine muscle  | LC-QqQ                    | Dasenaki et al. 2016 [23]                        | University of Athens (Greece) |
| 21                     | 62 Animal muscle  | LC-Q-Orbitrap             | Moretti et al. 2016 [24]                         | IZSUM (Italy)      |
| 22                     | 62 Milk           | LC-Q-Orbitrap             | Moretti et al. 2016 [25]                         | IZSUM (Italy)      |
| 23                     | >120 Animal tissues | LC-QqQ/LC-Q-TOF         | Anumol et al. 2017 [26]                          | USDA (USA)         |
| 24                     | 174 Bovine tissues | LC-QqQ                    | Lehotay et al. 2018 [27]                         | USDA (USA)         |
| 25                     | 44 Salmon         | LC-Q-TOF                  | Garpar et al. 2019 [28]                          | INIAV (Portugal)    |

*a OFCA = Official Food Control Authority; CFIA: Canada Food Inspection Agency; FERA: The Food and Environment Research Agency; LANAGRO: Laboratorio Nacional Agropecuario; INIAV: Instituto Nacional de Investigação Agrária e Veterinária; USDA: United States Department of Agriculture; IZSUM: Istituto Zooprofilattico Sperimentale dell’Umbria e delle Marche.*
The universities of Barcelona (Spain), Almeria (Spain), and Athens (Greece) have been the most active in this analytical field. LC-QqQ techniques are the most consolidated and most common multiclass procedures for veterinary drugs. These techniques have been mainly developed using this type of equipment [5,6,10–12,16,17,19,20,23,27]. In 2008–2009, the Official Food Control Authority of Zurich and the Dutch RIKILT Institute proposed, for the first time, the application of high-resolution (HR) mass spectrometry, based on time-of-flight (TOF) technology [7–9]. About three years later, the same Laboratory of Zurich, and the research group of Almeria University developed multiclass procedures for veterinary drugs, respectively, in meat, and milk, using LC-Orbitrap technique, a new MS analyzer, that was commercialized in 2005 [13,29]. Later, the introduction of benchtop hybrid high-resolution mass spectrometers (mainly, Q-TOF and Q-Orbitrap) produced further advantages in terms of selectivity and accuracy and, accordingly, these kinds of equipment has been more commonly applied (Table 1) [14,15,18,21,22,24–26,28,29].

Based on all the above, multiclass methods are no longer innovative procedures, and there is interest in their wide diffusion. The possibility of easy implementation and sustainable daily management, independent from the available LC-MS equipment. The aim of this work was to discuss the transfer of previously developed multiclass methods for more than sixty antibiotics in meat and milk from an LC-Q-Orbitrap platform to an LC-QqQ one [24,25]. The performance characteristics of the new LC-QqQ methods were estimated by means of full validation studies carried out according to European Commission Decision 2002/657/EC [30]. Finally, a comparison between the two techniques was carried out in the light of their cost-effectiveness in routine analysis of veterinary drug residues.

2. Results and Discussion

2.1. Optimization of LC-MS/MS Conditions

The choice of analytes has been carried out using the most administered antibiotics in farm. Only the classes of aminoglycosides and colistins were excluded, as their high polarity hampers the chromatographic retention, based on the reversed-phase mechanism (C18 column). On the other hand, the addition of ion-pairing agents on the mobile phase produced remarkable ion suppression, with detrimental effects on all the other analytes [24]. The chromatographic conditions were optimized starting from the parameters set for the LC-Q-Orbitrap methods. In order to profitably increase analyte retention, the percentage of methanol (eluent B) was reduced from 5% down to 2% (by volume). According to a typical reversed-phase mechanism, this change allowed us to obtain retention times of about 0.5 min higher than the initial tested conditions (Figure S1).

The MS conditions were established without the infusion of the individual solutions of analytes, but by setting the transitions on the basis of the ion fragments previously studied [24]. As shown in Table 2, except for a few exceptions, such as some beta-lactams ([M + Na]+), sulfanilamide ([M + H – NH3]+), spiramycin, neospiramycin, cefquinome, tildipirosin, tilmicosin, tulathromycin marker, and tulathromycin ([M + 2H]++), the selected precursor ion species were generally the protonated molecular ions ([M + H]+). For macrolides, it is not uncommon for the choice of bi-charged ions to be used as a precursor, due to their favorable abundance among the formed charged species [31]. The sample preparation was exactly the same as that previously optimized by Moretti et al. [24,25]; however, two internal standards (ISs) were replaced, in order to either, decrease costs (metacycline instead of tetracycline-d6), or to improve the MS response (cefadroxil-d3 instead of cefadroxil-d4). In this context, the ISs were not used for quantification purposes, but only to perform the internal quality control by checking the success of the analytical operations, during the routine application of the procedure as well as to monitor the run-to-run differences in the retention times [8]. For this purpose, at the beginning of sample treatment, IS were added at 10 µg·kg−1 and, before the release of the results, the presence (S/N > 3) of all eight compounds must be verified. The analyte quantification was achieved by matrix-matched curves (external standardization), which corrected the concentration for the relevant recovery factor [32]. The LC-QqQ chromatograms of a blank muscle, and of the same
spiked at 10 µg·kg\(^{-1}\), are reported in Figures 1 and 2, respectively. Eight representative analytes are shown, starting from the polar metabolite of florfenicol (florfenicol amine, RT = 3.4 min) to the last eluting compound (rifaximin, RT = 20.7 min). The analogous chromatograms are shown also for milk (Figures 3 and 4).

Figure 1. LC-QqQ chromatograms of a blank bovine muscle.

Figure 2. LC-QqQ chromatograms of a spiked bovine muscle (10 µg·kg\(^{-1}\)).
2.2. Method Validation

Selectivity requirements are reported in Commission Decision 2002/657/EC [30]. The ion ratio of the two selected transitions (Table 2), and their relative retention times (<2.5%), were checked to confirm analyte identification. Linearity in the matrix was evaluated with five-points matrix-matched curves: 2, 10, 33, 100, and 150 µg·kg\(^{-1}\). Therefore, levels higher than 150 µg·kg\(^{-1}\) had to be tested, and the final extract was diluted ten-fold or more, as reported in Tables S1 and S2. The linearity data are summarized in Table S3. For several analytes, the first calibration point (2 µg·kg\(^{-1}\)) had to be discarded, due to the scarce response. In other more critical cases (e.g., cefacetrile in meat/muscle, tildipirosin and tulathromycin markers in milk) additional points have been removed. Since Commission Decision 657/2002/EC [30] does not furnish precise criteria for evaluating linearity, the
tulathromycin markers in milk) additional points have been removed. Since Commission Decision 657/2002/EC [30] does not furnish precise criteria for evaluating linearity, the “Guidance document on analytical quality control and validation procedures for pesticide residues analysis in food and feed” was followed [33]. The percentage deviation of the back-calculated concentrations ($C_{\text{measured}}$) from the true concentrations ($C_{\text{true}}$) was calculated (1):

$$\text{Deviation} \ (\%) = \left( \frac{C_{\text{measured}} - C_{\text{true}}}{C_{\text{true}}} \right) \cdot 100$$

(1)

Table 2. Summary of the selected reactions transitions (SRM) monitored for the sixty-four targeted analytes.

| No. | Analyte                  | Retention Time (min) | Adduct ($m/z$) | Precursor Ion ($m/z$) | Product Ions ($m/z$) | Collision Energy (eV) |
|-----|--------------------------|----------------------|----------------|-----------------------|----------------------|-------------------------|
| 1   | Sulfaguanidine           | 2.85                 | [M + H]$^+$    | 215.1                 | 92.0                 | 15                      |
| 2   | Florfenicolamine         | 3.20                 | [M + H]$^+$    | 248.1                 | 230.1                | 10                      |
| 3   | Sulfanilamide            | 3.30                 | [M + H − NH$_3^+$] | 156.0               | 92.0                 | 12                      |
|     | Sulfanilamide-13C6       | 3.30                 | [M + H − NH$_3^+$] | 162.0               | 98.1                 | 13                      |
| 4   | Desacetylcephapyrin      | 6.80                 | [M + H]$^+$    | 382.1                 | 222.0                | 20                      |
| 5   | Amoxicillin              | 8.30                 | [M + H]$^+$    | 366.1                 | 304.1                | 10                      |
| 6   | Sulfadiazine             | 8.50                 | [M + H]$^+$    | 251.1                 | 108.0                | 26                      |
| 7   | Sulfathiazole            | 9.20                 | [M + H]$^+$    | 256.0                 | 156.0                | 15                      |
| 8   | Cephapyrin               | 9.45                 | [M + H]$^+$    | 424.1                 | 252.1                | 28                      |
| 9   | Sulfapyridine            | 9.50                 | [M + H]$^+$    | 250.1                 | 156.0                | 26                      |
| 10  | Tildipirosin             | 9.90                 | [M+2H]$^{2+}$  | 367.7                 | 281.2                | 20                      |
| 11  | Sulfamerazine            | 9.90                 | [M + H]$^+$    | 265.1                 | 108.0                | 27                      |
| 12  | Cefquinome               | 10.00                | [M + 2H]$^{2+}$ | 265.1                | 134.2                | 20                      |
| 13  | Cefacetriple             | 10.15                | [M + Na]$^+$   | 362.0                 | 258.0                | 10                      |
| 14  | Cefalonium               | 10.50                | [M + H]$^+$    | 459.1                 | 302.0                | 10                      |
| 15  | Lincomycin               | 10.50                | [M + H]$^+$    | 407.2                 | 337.0                | 10                      |
| 16  | Tulathromycin marker     | 10.60                | [M + 2H]$^{2+}$ | 289.0                | 158.3                | 17                      |
| 17  | Thiamphenicol            | 10.60                | [M + H]$^+$    | 356.0                 | 308.0                | 20                      |
| 18  | Epitetracycline          | 10.60                | [M + H]$^+$    | 445.2                 | 410.2                | 20                      |
| 19  | Trimethoprim             | 10.70                | [M + H]$^+$    | 291.1                 | 261.1                | 30                      |
Table 2. Cont.

| №  | Analyte           | Retention Time (min) | Adduct (m/z) | Precursor Ion (m/z) | Product Ions (m/z) | Collision Energy (eV) |
|----|-------------------|----------------------|--------------|--------------------|-------------------|-----------------------|
| 20 | Marbofloxacin     | 10.80                | [M + H]⁺     | 363.1              | 276.1             | 14                    |
| 21 | Sulfamethazine    | 11.10                | [M + H]⁺     | 279.1              | 320.1             | 14                    |
| 22 | Epoxymetrocycline | 11.35                | [M + H]⁺     | 461.2              | 426.1             | 20                    |
| 23 | Norfloxacin       | 11.50                | [M + H]⁺     | 320.1              | 337.1             | 30                    |
| 24 | Tetracycline      | 11.50                | [M + H]⁺     | 445.2              | 392.1             | 30                    |
| 25 | Cefalexine        | 11.70                | [M + H]⁺     | 348.1              | 158.0             | 10                    |
| 26 | Oxytetracycline   | 11.80                | [M + H]⁺     | 461.2              | 426.1             | 20                    |
| 27 | Ciprofloxacin     | 11.80                | [M + H]⁺     | 332.1              | 245.1             | 23                    |
| 28 | Enrofloxacin      | 11.90                | [M + H]⁺     | 360.2              | 316.1             | 19                    |
| 29 | Tulathromycin     | 11.90                | [M + 2H]⁺⁺   | 404.0              | 321.4             | 18                    |
| 30 | Danofloxacin      | 11.95                | [M + H]⁺     | 358.2              | 340.1             | 22                    |
| 31 | Cefazolin         | 12.00                | [M + H]⁺     | 455.0              | 323.1             | 10                    |
| 32 | Sulfamethoxazole  | 12.10                | [M + H]⁺     | 254.1              | 156.0             | 20                    |
| 33 | Difloxacin        | 12.30                | [M + H]⁺     | 400.1              | 156.0             | 16                    |
| 34 | Ampicillin        | 12.30                | [M + H]⁺     | 350.1              | 299.1             | 26                    |
| 35 | Sulfamonomethoxine| 12.30                | [M + H]⁺     | 281.1              | 231.1             | 20                    |
| 36 | Florfenicol       | 12.40                | [M + H]⁺     | 358.0              | 156.0             | 16                    |
| 37 | Cefoperazone      | 12.60                | [M + H]⁺     | 646.1              | 356.1             | 18                    |
| 38 | Sarafloxacin      | 12.60                | [M + H]⁺     | 386.1              | 106.1             | 20                    |
| 39 | Epichlortetracycline| 12.85               | [M + H]⁺     | 479.1              | 160.0             | 20                    |
| 40 | Neospiramycin     | 13.40                | [M + 2H]⁺⁺   | 350.2              | 156.0             | 20                    |
| 41 | Chlortetracycline | 13.80                | [M + H]⁺     | 479.1              | 154.0             | 16                    |
| 42 | Spiramycin        | 14.05                | [M + 2H]⁺⁺   | 422.3              | 174.1             | 20                    |
| 43 | Sulfadimethoxine  | 14.40                | [M + H]⁺     | 311.1              | 156.0             | 20                    |
| 44 | Sulfaquinoxaline  | 14.80                | [M + H]⁺     | 301.1              | 92.1              | 30                    |
Table 2. Cont.

| N°  | Analyte               | Retention Time (min) | Adduct \((m/z)\)     | Precursor Ion \((m/z)\) | Product Ions \((m/z)\) | Collision Energy (eV) |
|-----|-----------------------|----------------------|-----------------------|-------------------------|-------------------------|-----------------------|
| 45  | Oxolinic Acid         | 15.00                | \([M + H]^+\)         | 262.1                   | 216.0                   | 29                    |
| 46  | Ceftriaxone           | 15.10                | \([M + H]^+\)         | 524.0                   | 244.0                   | 20                    |
| 47  | Metacycline           | 15.15                | \([M + H]^+\)         | 527.0                   | 244.1                   | 15                    |
| 48  | Gamithromycin         | 15.40                | \([M + H]^+\)         | 443.1                   | 442.6                   | 16                    |
| 49  | Tilmicosin            | 15.70                | \([M + 2H]^{++}\)     | 435.3                   | 695.5                   | 20                    |
| 50  | Doxycycline           | 15.50                | \([M + H]^+\)         | 445.2                   | 174.1                   | 30                    |
| 51  | Nalidixic Acid\(^a\)  | 16.80                | \([M + H]^+\)         | 233.1                   | 159.0                   | 30                    |
| 52  | Tiamulin              | 17.10                | \([M + H]^+\)         | 494.3                   | 192.1                   | 20                    |
| 53  | Penicillin G          | 17.15                | \([M + Na]^+\)        | 357.1                   | 198.1                   | 20                    |
| 54  | Penicillin G-d7       | 17.15                | \([M + Na]^+\)        | 364.0                   | 182.0                   | 20                    |
| 55  | Flumequine            | 17.20                | \([M + H]^+\)         | 262.1                   | 202.0                   | 33                    |
| 56  | Tylosina A            | 17.40                | \([M + H]^+\)         | 916.5                   | 174.1                   | 36                    |
| 57  | Erythromycin          | 17.60                | \([M + H]^+\)         | 734.5                   | 772.5                   | 28                    |
| 58  | 3-O-Acetyltetrazole    | 17.75                | \([M + H]^+\)         | 174.0                   | 772.5                   | 28                    |
| 59  | Oxacillin             | 18.20                | \([M + Na]^+\)        | 424.1                   | 265.1                   | 20                    |
| 60  | Penicillin V          | 18.20                | \([M + Na]^+\)        | 373.1                   | 182.0                   | 20                    |
| 61  | Cloxacillin           | 18.50                | \([M + Na]^+\)        | 458.1                   | 214.0                   | 20                    |
| 62  | Valnemulin            | 19.10                | \([M + H]^+\)         | 565.4                   | 299.0                   | 20                    |
| 63  | Dicloxacillin         | 19.20                | \([M + Na]^+\)        | 492.0                   | 299.0                   | 20                    |
| 64  | Nacifloxin            | 19.30                | \([M + H]^+\)         | 415.1                   | 171.1                   | 34                    |
| 65  | Tilmofloxin           | 19.45                | \([M + H]^+\)         | 1042.6                  | 199.1                   | 13                    |
| 66  | Rifaximin             | 20.60                | \([M + H]^+\)         | 786.4                   | 754.3                   | 20                    |

\(^a\) Acquired only in milk.

For each calibration point, it was verified that its value was not more than ± 20%. As an example, the calibration data of six analytes, belonging to different antibiotic families, are reported in Table S4 and Figures S2 and S3.

The overall recoveries and precisions data are listed in Table 3. For meat, seven validation levels were performed in the range 10–1500 µg·kg\(^{-1}\), whereas, in milk, five levels were investigated (10–333 µg·kg\(^{-1}\)), with an additional concentration at 2 µg·kg\(^{-1}\) to check amoxicillin, ampicillin, and penicillin G accuracy at \(\frac{1}{2}\) MRL, as required by the Commission Decision 2002/657/EC [30]. Moreover, in milk, two additional molecules were tested with respect to the original group of 62 compounds, that is, the two quinolones, nalidixic acid, and norfloxacin.
Table 3. Precision, recovery and matrix effect (muscle and milk).

| Analyte ab | Muscle (averages) | Milk (averages) |
|------------|------------------|-----------------|
|            | CV pooled (%)    | CV pooled (%)   | Rec (%) | ME (%) | CV pooled (%) | CV pooled (%) | Rec (%) | ME (%) |
| Sulfaguanidine | 5.8 10 83 | -14 | 5.0 14 | 61 253 |
| Florfenicol Amine | 3.2 6.1 85 | -22 | 2.5 3.8 | 94 -13 |
| Sulfanilamide | 6.6 8.9 74 | -35 | 5.8 12 | 66 -21 |
| Desacylcephalosphorin | 7.6 7.3 76 | -1 | 5.9 6.0 | 91 -21 |
| Amoxicillin | 4.5 6.3 64 | -1 | 5.8 5.8 | 89 -10 |
| Sulfadiazine | 5.1 8.2 86 | -18 | 4.8 8.6 | 74 -16 |
| Sulfathiazole | 5.2 8.0 83 | -6 | 5.2 8.3 | 71 -15 |
| Cephapirin | 6.9 7.8 75 | 1 | 12 12 | 94 -5 |
| Sulfapyridine | 4.6 7.2 85 | 13 | 5.8 9.5 | 67 -13 |
| Tildipirosin | 6.2 10 72 | -8 | 6.0 20 | 87 5 |
| Ceftiuomine | 6.1 7.2 97 | -4 | 11 19 | 78 -16 |
| Sulfamerazine | 3.8 5.9 89 | 11 | 6.7 8.7 | 70 -13 |
| Cefacetile | 12 13 80 | -26 | 22 27 | 92 -5 |
| Cefaloridine | 6.7 7.3 78 | 3 | 8.7 8.7 | 93 -6 |
| Lincomycin | 4.3 7.2 83 | -12 | 2.3 4.4 | 92 30 |
| Epitetracycline | 6.2 9.2 66 | 22 | 4.7 7.6 | 96 5 |
| Trimethoprim | 3.4 7.8 90 | -3 | 2.7 4.9 | 94 4 |
| Thiampencile | 10 11 87 | -13 | 13 13 | 92 -13 |
| Tulathromycin | 5.6 8.6 81 | -13 | 8.7 26 | 81 -18 |
| Marbofloxacin | 6.1 7.0 87 | -27 | 4.3 4.9 | 96 -11 |
| Sulfamethazine | 4.1 7.2 85 | -1 | 7.8 14 | 68 -13 |
| Epipyruratecine | 8.8 13 62 | 40 | 13 15 | 90 -3 |
| Norfloxacin | - - - | - | 7.0 8.0 | 94 3 |
| Tetracycline | 6.3 9.4 71 | 27 | 4.5 5.0 | 91 40 |
| Cefalexin | 6.2 8.4 64 | 1 | 6.2 6.7 | 90 -7 |
| Oxytetracycline | 6.7 8.1 63 | 10 | 4.4 5.2 | 90 1 |
| Ciproflaxacin | 7.5 8.4 81 | -25 | 6.1 7.5 | 95 -10 |
| Enrofloxacin | 4.7 6.6 93 | -16 | 4.1 5.9 | 99 -1 |
| Tulathromycin | 8.3 16 69 | 10 | 7.5 13 | 94 5 |
| Danofloxacin | 5.7 7.2 90 | -17 | 4.2 5.0 | 97 3 |
| Cefazolin | 8.4 9.0 83 | -8 | 14 14 | 94 -11 |
| Sulfadoxethasole | 7.7 9.7 88 | -16 | 6.7 6.7 | 84 -24 |
| Difluoxacin | 5.0 7.4 93 | -15 | 3.3 4.2 | 96 -13 |
| Ampicillin | 6.6 8.0 68 | -2 | 9.4 10 | 88 -10 |
| Sulfadimoxemethone | 4.6 7.4 86 | 0 | 6.4 9.9 | 78 -19 |
| Florfenicol | 9.8 16 90 | -17 | 13 13 | 94 -28 |
| Cefoperazone | 6.8 8.4 85 | -13 | 16 18 | 103 -25 |
| Sarafloxacine | 5.8 7.4 86 | -26 | 4.8 6.6 | 99 -22 |
| Epichlorotetrazercine | 9.3 13 71 | 65 | 7.4 11 | 100 22 |
| Neosipiramycin | 7.8 16 67 | 12 | 7.3 12 | 86 13 |
| Chlorotetrazercine | 5.8 7.7 69 | 47 | 5.7 7.2 | 92 48 |
| Spirinmycin | 8.4 17 74 | 20 | 4.5 7.6 | 91 21 |
| Sulfadimethazine | 4.5 8.1 88 | -12 | 3.9 3.9 | 90 -29 |
| Sulfadinoxaline | 6.1 7.7 86 | -26 | 4.6 4.8 | 91 -38 |
| Oxylinic Acid | 4.9 6.7 97 | 4 | 2.6 6.6 | 96 -3 |
| Cefistour | 7.5 9.7 72 | -21 | 6.7 7.1 | 95 -24 |
| Gamithromycin | 5.6 7.1 94 | 55 | 3.2 4.8 | 98 26 |
| Tilmicosin | 6.9 10 88 | 49 | 3.2 4.4 | 95 38 |
| Doxyccycline | 7.0 9.5 69 | 1 | 6.6 7.4 | 95 10 |
| Nalixidic Acid | - - - | - | 3.6 6.0 | 94 -3 |
| Penicillin G | 7.9 9.0 85 | -21 | 12 13 | 92 37 |
| Tiamulin | 9.3 13 88 | -21 | 2.5 4.1 | 98 -5 |
| Flumeqine | 4.3 7.3 95 | -3 | 2.9 4.5 | 95 52 |
| Tylosin | 7.7 15 85 | 29 | 2.5 4.8 | 96 54 |
| Erythromycin A | 4.9 8.6 89 | -27 | 4.7 12 | 67 -21 |
| 3-O-Acetyltulosin | 9.3 16 88 | 42 | 3.7 5.0 | 95 53 |
| Oxacillin | 6.0 11 83 | -29 | 8.0 8.5 | 100 1 |
| Penicillin V | 7.9 11 85 | -28 | 7.5 7.7 | 99 6 |
where CV were added immediately prior to LC injection. The data in Table 3 summarize the average recoveries and CC capabilities (CCβ) at whatever MRL value. Therefore, the CVwR,pooled can also be used to obtain CCα and CCβ, where new MRLs were fixed in Regulation 37/2010 [1], maximizing the cost-effectiveness of the validation study. The decision limit and detection capability were calculated as follows (equations 3 and 4):

\[ CC_{\alpha \text{MRL}} = MRL + 1.64 \cdot CV_{wR,pooled} \cdot MRL \]  

\[ CC_{\beta \text{MRL}} = CC_{\alpha \text{MRL}} + 1.64 \cdot CV_{wR,pooled} \cdot CC_{\alpha \text{MRL}} \]  

In this work, the classical validation scheme (0.5 MRL, MRL and 1.5 MRL), described in Commission Decision 2002/657/EC, was not applied. Paragraph 3.1.3. of the same decision allows the introduction of alternative models [30] and, since the validation studies of multiclass procedures have to consider dozens of MRLs, which can vary also in function of the animal species, the adoption of progressive validation levels, that are equal for all the analytes, was fully justified. On the other hand, when the Commission Decision was issued (2002), the development of multiclass procedures for the control of veterinary drug residues was not initiated. The spiking ranges were chosen, considering, on the one side, the reachable concentrations, and, on the other side, the relevant MRLs [1] in all the couplings analyte/matrix. Preliminary experiments demonstrated that, at levels lower than 10 µg·kg⁻¹, the precision of several amphenicols, macrolides, beta-lactams, and tetracyclines became unsatisfactory.

The recovery factors (Rec) were established by comparing the peak area of each compound in the spiked samples against the peak area in the matrix matched standards, by which the antibiotics were added immediately prior to LC injection. The data in Table 3 summarize the average recoveries obtained in the whole validation range. In muscles, all recoveries were higher than 70%, except the majority of tetracyclines (62–69%), three beta-lactams (64–68%), and two macrolides (neospiromycin, 67% and tulathromycin, 69%). Analogously, in milk, recoveries higher than 70% were generally obtained in the whole validation range. In muscles, all recoveries were higher than 70%, except for the more polar sulfonamides (61–70%) and one macrolide (erythromycin A, 67%). Since the quantification was performed with an external standardization, the raw results were always corrected for the relevant recovery factor, in order to correct the systematic error [32]. With regard to precision, the coefficients of variations (CVs) were calculated at each validation level both, repeatedly, and in intra-lab reproducibility conditions (CVr, and CVwR, respectively), by applying ANOVA. Moreover the CVwR (and CVr) were pooled to obtain an overall precision index, namely CVwR,pooled (2),

\[ CV_{wR,pooled} = \sqrt{(n_1-1)CV^2_{wR1} + (n_2-1)CV^2_{wR2} + \ldots + (n_n-1)CV^2_{wRn}} / (n_1 - 1) + (n_2 - 1) + \ldots + (n_n - 1) \]  

where CVwR1, CVwR2 ... CVwRn were the coefficients of variation at the increasing levels 1, 2 ... n; n1, n2 ... n were the number of replicates at each level [34]. For a certain analyte, the CVwR,pooled give a single estimate of precision, which can be applied to calculate decision limits (CCα) and detection capabilities (CCβ) at whatever MRL value. Therefore, the CVwR,pooled can also be used to obtain CCα and CCβ, where new MRLs were fixed in Regulation 37/2010 [1], maximizing the cost-effectiveness of the validation study. The decision limit and detection capability were calculated as follows (equations 3 and 4):

\[ CC_{\alpha \text{MRL}} = MRL + 1.64 \cdot CV_{wR,pooled} \cdot MRL \]  

\[ CC_{\beta \text{MRL}} = CC_{\alpha \text{MRL}} + 1.64 \cdot CV_{wR,pooled} \cdot CC_{\alpha \text{MRL}} \]  

| Analyte   | CVwR,pooled (%) | CVr,pooled (%) | Rec (%) | ME (%) | CVwR,pooled (%) | CVr,pooled (%) | Rec (%) | ME (%) |
|-----------|-----------------|----------------|---------|--------|-----------------|----------------|---------|--------|
| Cloxacillin | 8.2             | 11             | 84      | −27    | 9.8             | 12             | 110     | −25    |
| Valnemulin | 19              | 31             | 75      | −26    | 2.7             | 5.4             | 108     | 55     |
| Dicloxacillin | 6.7          | 10             | 81      | −25    | 13              | 15             | 99      | −10    |
| Nafacillin | 5.0             | 8.2            | 84      | −7     | 5.0             | 5.4             | 99      | −19    |
| Tylvalosin | 9.0             | 19             | 93      | 50     | 5.4             | 6.9             | 101     | 90     |
| Rifaximine | 9.0             | 12             | 91      | 33     | 4.8             | 9.6             | 98      | 7      |

Note: a Nalidixic acid and norfloxacin were not included in muscle method since these antibiotics were introduced later; b For valnemulin (muscle), cefacetrile (milk) and ceftiuquine (milk) the method can be used only for screening purposes (inadequate accuracy); c Values of matrix effect (ME) in bold are considered significant (>20%).
In Tables S4 and S5, the MRLs of the 64 antibiotics, in various food-producing animal species, and in bovine milk, together with the relevant CCαs and CCβs, are listed. The MRLs are those reported in the last consolidated text of Regulation 37/2010 [1,35]. In muscles, valnemulin demonstrated high imprecision (CV_{wR,pooled} = 31%) and, therefore, for these compounds, the developed procedure could be only used for screening purposes (Table 3). For all the other antibiotics, CV_{wR,pooled} was always lower than 20%. On the other hand, in milk, cefacetrile and tulathromycin marker demonstrated insufficient precision (CV_{wR,pooled} > 22%). Matrix effects (ME%) listed in Table 3 were calculated as follows (equation 5),

\[
ME(\%) = \frac{b_{MM} - b_S}{b_S} \times 100
\]  

where \(b_{MM}\) and \(b_S\) were the slopes of matrix matched curves, and solvent standard curves, i.e., curves prepared in ammonium acetate 0.2 M, respectively. In the whole, although the sample purification was scarce, the matrix effects (suppression or enhancement) were limited and very few compounds demonstrated ME (%) higher than [50]%. This was probably because the long chromatographic run (30.5 min) allowed the distribution of matrix-interfering compounds and analytes, from preventing excessive bunching [26].

Since the signal-to-noise approach (S/N) is rather subjective [36], “operative” (fit for purpose) LOD and LOQ were fixed by examining the precision at each validation level (Table S7). All the compounds were detectable at the first concentration, i.e., 2 μg·kg\(^{-1}\) for amoxicillin, ampicillin, and penicillin G in milk and 10 μg·kg\(^{-1}\) for all the others. The only exception was cefacetrile, which is a scarcely ionizable molecule and, therefore, detectable and quantifiable from 33 μg·kg\(^{-1}\) in milk (CV_{r} = 13%, CV_{wR} = 14%, recovery = 76%) and only detectable in milk (insufficient precision). A satisfactory accuracy for both amoxicillin and ampicillin was obtained at 2 μg·kg\(^{-1}\), whereas penicillin G demonstrated unsatisfactory precision at this level (CV_{r} = 23%, CV_{wR} = 26%) and, therefore, this beta-lactam could be quantified only starting from 10 μg·kg\(^{-1}\) (CV_{r} = 7.5%, CV_{wR} = 11%). Therefore, penicillin G, a fundamental drug for the treatment of sub-clinical mastitis in lactating cows, could not be quantified in milk at \(\frac{1}{2}\) MRL (2 μg·kg\(^{-1}\)) and the method was suitable only for screening purpose [30]. In Figure S4 the LC-QqQ chromatograms of these three compounds are shown in a blank milk sample and in the same sample spiked at 2 μg·kg\(^{-1}\).

2.3. Comparison of LC-QqQ and LC-Q-Orbitrap Methods

Comparing the recovery factors of the methods developed in meat, similar results were always obtained (differences < 15%), except for cefquinome, which demonstrated a higher recovery when LC-QqQ was applied (+ 26%: 97% LR vs. 71% HR) and valnemulin which, nevertheless, was not accurately quantifiable with the LR procedure, as discussed above. The recovery differences are visualized in Figure S5. Examining the data of the more polar cephalosporins (desacetylcephapirin, cepapirin, cefacetrile and cefalonium), cefquinome recovery appeared suspect (over-estimated) using QqQ technique. Since the sample preparation protocol was the same, this difference should be attributed to an instrumental technique. Interestingly, cefquinome co-eluted with sulfamerazine and, in addition, accidentally their precursor ion had the same nominal mass charge ratio i.e., \(m/z\) 265 (Table 2). In our laboratory, at the beginning of the development of multiclass methods for antibiotics in food (2014), two separate matrix-matched curves were prepared, one for beta-lactams and another for all other analytes [24]. This measure was precautionary in order to avoid the possible negative effects of methanol, contained in the intermediate solution of antibiotics other than beta-lactams (see Section 2.2) on beta-lactam stability, as described in the literature [37,38]. In saying that, the artefacts in the quantification of cefquinome and/or sulfamerazine could occur if “hidden” transitions were shared between these two compounds. This means that a transition, monitored only for one of the two analytes (Table 2), was shared by the other one, too. In order to verify this hypothesis, two individual solutions (50 ng·mL\(^{-1}\)) were separately injected, by simultaneously monitoring the four relevant SRMs (Figure S6). It was evident that sulfamerazine shared a “hidden” transition with cefquinome (\(m/z\) 265 >
m/z 199—left side of Figure S6), but also vice versa (m/z 265 > m/z 156—right side of Figure S6). For sulfamerazine the fragment ion species at m/z 199 was formed by the rearrangement ion, by losing H$_2$SO$_2$ from the protonated molecule [39]. On the other hand, for ceftiraxone, the ion m/z 156 derived by the cleavage of C-C bond between oxime and the carbonyl group of C$_7$ amide ([C$_5$H$_6$N$_3$OS]$_2$) of the beta-lactam ring [40]. However, from a quantitative point of view, sulfamerazine could notably affect the peak area of cefquinome, but the contrary was much less, since sulfamerazine responded more significantly than cefquinome (about 4.9 x 10$^6$ vs. 1.1 x 10$^6$). Accordingly, when sulfamerazine was co-present, cefquinome concentration was significantly over-estimated. Later, observing that, in the adopted experimental conditions, beta-lactams were not deteriorated by methanol, the validation study in milk was performed by preparing only one matrix-matched calibration curve with all the analytes, including beta-lactams. In summary, although the development of LR procedures has been very fast and effective, due to previously-studied conditions [24,25], for one analyte, i.e., cefquinome, the choice of the precursor ion should be re-evaluated.

In Figure S7 the differences between LR and HR recovery factors in milk are shown. Tulathromycin marker and cefquinome had better recovery rates using HR detection, whereas valnemulin, cloxacillin, and rifaximin, showed better results using the LR system. As reported in our previous paper [25], LC-Q-Orbitrap suffers from “post interface ion suppression”, which consists of instrument saturation when intense matrix-related compounds are present [41]. This phenomenon was more pronounced for the last eluting compounds, such as valnemulin, cloxacillin, and rifaximin, which explains the observed data in milk extracts. These have more interfering substances with respect to muscle [25]. Comparing the precision data (intra-laboratory reproducibility, CV$_{wR,pooled}$, see Tables S8 and S9), remarkable differences (≥15%) between the two techniques were observed only in milk and, again, tulathromycin marker and cefquinome revealed the worse performances when determined by LC-QqQ. CV$_{wR,pooled}$ of tylosin, cloxacillin, and tylvalosin were about 10% higher when analyzed by LC-Q-Orbitrap (Figure S9).

According to accreditation rules [42], since 2014 our laboratory participated in Proficiency Test Schemes in meat and milk, by applying the LC-Q-Orbitrap methods in these products. Some of the stored test materials were then re-tested, by applying the new developed procedures. The results, together with the consensus values assigned by the Organizers, are listed in Table 4. Examining the acceptability ranges, satisfactory z-scores would have been always obtained, except in the case of amoxicillin in milk (sample code: MI1532-A1). This latter result was explainable with the well-known instability of penicillin antibiotics [43,44].
### Table 4. Participation in Proficiency Test Schemes: comparison between methods.

| Sample Code/Year | Matrix        | Analyte          | Found Concentration (µg·kg⁻¹) | Consensus Value (µg·kg⁻¹) | Acceptability Range (µg·kg⁻¹) |
|------------------|---------------|------------------|-------------------------------|---------------------------|-------------------------------|
| MI1432-A1/2014   | Milk          | Sulfamethazine   | 144                           | 103                       | 57–150                        |
| MI1432-A2/2014   | Milk          | Amoxicillin      | 5                             | ND                        | Not assigned                  |
| M1435-A1/2014    | Pig muscle    | Sulfamethazine   | 88                            | 69                        | 36–102                        |
| M1435-A2/2014    | Pig muscle    | Sulfadimethoxine | 32                            | 27                        | 12–42                         |
| M1433-A2/2014    | Turkey muscle | Ciprofloxacin    | 5.5                           | 5.6                       | 3.2–8.1                       |
| MI1433-A2/2014   | Turkey muscle | Enrofloxacin     | 173                           | 160                       | 92–227                        |
| MI1532-A1/2015   | Milk          | Amoxicillin      | 16                            | 14                        | 5.6–22                        |
| MI1532-A2/2015   | Milk          | Sulfamethazine   | 165                           | 134                       | 75–191                        |
| M1623-A1/2016    | Milk          | Flumequine       | 91                            | 88                        | 47–129                        |
| M1623-A2/2016    | Milk          | Oxytetracycline  | 93                            | 91                        | 49–132                        |
| MI1715-A2/2017   | Milk          | Danofloxacin     | 91                            | 74                        | 39–109                        |
| 484 (material C) | Bovine Muscle | Marbofloxacin    | 178                           | 170                       | 100–240                       |
| 334/2019         | Bovine muscle | Oxytetracycline  | 89                            | 106                       | 59–152                        |
| 334/2019         | Bovine muscle | Ciprofloxacin    | 10                            | NA                        | -                             |
| 544/2019         | Bovine muscle | Enrofloxacin     | 82                            | NA                        | -                             |
| 544/2019         | Bovine muscle | Tylosin A        | 54                            | NA                        | -                             |

*a* Test Veritas, Padova, Italy; *b* RIKILT, Wageningen, Netherlands; *c* The final Report is not yet available.
In summary, the main advantages and disadvantages of the two techniques are undoubtedly, the QqQ analyser, which only involves only a kind of acquisition, i.e., SRM mode. On the contrary, Q-Orbitrap forces more complex experiments, also because the detection of analytes at trace levels is complicated by the “post interface ion suppression” phenomenon. On this subject, we demonstrated that, in certain chromatographic regions, for milk it is not possible to reach the required limits using full-scan experiments, since the massive presence of interfering substances can drastically worsen the sensitivity [25]. With regard to the sample throughput, the sample preparation protocol is identical and, therefore, there is no great difference. Moreover, it must be highlighted that some performances of LR system are due to the obsolescence of the available equipment. For example, most likely, a more recent LR platform could reach comparable LODs with HR, i.e., lower than 10 μg·kg⁻¹. All that said, the LC-QqQ technique is more suitable for routine laboratories, considering its user-friendliness and lesser cost (about three time lesser than LC-Q-Orbitrap).

3. Experimental

3.1. Chemical and Reagents

Acetonitrile (ACN) and methanol (LC-MS grade) were from Carlo Erba Reagents (Milan, Italy). Formic acid (50%) and N,N’-dimethylformamide (DMF) were purchased from Sigma-Aldrich (St. Louis, MO, USA). EDTA sodium salt dehydrate and ammonium acetate were provided by Sigma-Aldrich. Ultra-pure deionized water was generated by a Milli-Q purification apparatus (Millipore, Bedford, MA, USA). Amoxicillin, ampicillin, cloxacillin, dicloxacillin, nafcillin, oxacillin, penicillin G (benzylpenicillin), penicillin G-d7, penicillin V (phenoxyethylpenicillin), cefalonium, cefoperazone, ceftiquione, cefotiofur, cephalexin, ciprofloxacin, danofloxacin, difloxacin, enrofloxacin, flumequine, marbofloxacin, nalidixic acid, norfloxacin, oxolinic acid, sarafloxacin, erithromycin A, spiramycin I, tylosin A, tilimicosin, sulfadiazine, sulfaguanidine, sulfadimethoxine, sulfamerazine, sulfamethazine (sulfadimidine), sulfamethoxazole, sulfanilamide, sulfapyridine, sulfafloxacine, sulfathiazole, trimethoprim, chlorotetracycline, doxycycline, metacycline, oxytetracycline, tetracycline, florfenicol, florfenicol amine, tilmicosin, lincomycin, rifaximin, tiamulin and valnemulin were obtained from Sigma-Aldrich. Sulfamonomethoxine was purchased from Dr. Ehrenstorfer (Augsburg, Germany); cefazolin, cefadroxil, cefotiofur-d3, cephapirin, desacetylcephapirin, florfenicol-d3, 3-O-acetyltirosin, gamithromycin, neospiramycin, spiramycin I-d3, tildipirosin, tulathromycin, tylvalosin, 4-epi-chlortetracycline, 4-epi-tetracycline, 4-epi-oxytetracycline, and tulathromycin marker (CP-60,300) were purchased from TRC Inc. (Toronto, Canada); sulfamethazine-¹³C₂, sulfanilamide-¹³C₁₂ and enrofloxacin-d₅ were obtained from WITEGA (Berlin, Germany).

3.2. Standard Solutions

Individual stock standard solutions of 100 μg·mL⁻¹ were prepared with methanol (amphenicols, lincosamides, macrolides, pleuromutilins, sulphonamides, tetracyclines and trimethoprim). The solubilization and storage conditions were previously studied [24]. Beta lactams were solubilized in H₂O/ACN 75/25 (v/v), except ceftiofur (DMF). Quinolones in MeOH/H₂O 80/20 (v/v), except ciprofloxacin, nalidixic acid, norfloxacin, enrofloxacin and oxolinic acid (DMF). Rifaximin was prepared in MeOH/H₂O 50/50 (v/v). The stock solutions were stored at −20 °C with variable storage times: From 1 month (ceftiquione) to 24 months (sulphonamides). Working solutions (10, 1 and 0.1 μg·mL⁻¹) were prepared from the relevant stock solutions diluting with H₂O/ACN 75/25 (v/v) for beta-lactams and with methanol for all the other antibiotics. The solutions of internal standards were prepared according to their native compound or class.

3.3. LC-MS-MS Conditions

LC-MS/MS measurements were performed by a Surveyor LC pump, coupled with a triple quadrupole mass spectrometer (TSQ Quantum Ultra, Thermo Fisher, San Jose, CA, USA), an electrospray
source included, and operating in a positive ionization mode. Separation was achieved on a Poroshell 120 EC-C18 column (3.0 x 100 mm; 2.7 µm particle diameter), which was connected to a guard column Poroshell (2.1 x 5 mm), both from Agilent Technologies (Santa Clara, CA, USA). The flow rate used was 0.25 mL·min⁻¹ and the column temperature set at 30 °C. Mobile phase A was an aqueous solution 0.1% (v/v) formic acid and eluent B methanol. The gradient profile started at 2% eluent B for 1 min and increased linearly up to 95% B in 19.5 min; this condition was maintained for 5 min before returning to initial condition in 1 min (2% B) and held for 4 min to equilibrate the column. The sample temperature was kept at 16 °C and the injection volume 10 µL. For MS detection, the parameters were the follows: Capillary temperature 300 °C, vaporizer 320 °C, spray voltage 3 kV, and a resolution setting of Q1 and Q3 m/z 0.7. Sheath gas and auxiliary gas (nitrogen) pressures were set at 35, and 15 arbitrary units, respectively. Collision gas (argon) pressure: 1.5 mtorr. The collision energies, that were associated with each transition, are listed in Table 2.

3.4. Sample Preparation

The sample preparation was described elsewhere [24,25]. Briefly, (1.50 ± 0.01) g of minced muscle or milk were weighed in a 50 mL Falcon tube. The sample was spiked with: (i) 15 µL of the solution of the two internal standards (ISs) of beta-lactams at 1 µg·mL⁻¹ (ceftiofur-d₃ and penicillin G-d₇); (ii) 15 µL of the solution of the other six ISs (sulfanilamide₁³C₆, sulfamethazine₁³C₆, enrofloxacin-d₅, florfenicol-d₃, spiramycin-d₃ and metacycline) at 1 µg mL⁻¹. For muscles, one hundred microliters of 0.1 M of EDTA was then added, and the sample was extracted with 3 mL of a mixture of acetonitrile/water 80/20 (v/v). Milk was extracted with one milliliter of 0.1 M of EDTA and 3 mL of acetonitrile. A second extraction with 3 mL of pure acetonitrile was performed for both matrices. After centrifugation, the reunited extracts were evaporated and solubilized in 1.5 mL of ammonium acetate 0.2 M. Ten µL was injected in the LC system.

3.5. Method Validation

The validation was carried out following the Commission Decision 2002/657/EC [30]. To test the selectivity, blank muscle samples, belonging to the main animal species (bovine, swine and poultry) and bovine milk samples from different origins, were analyzed. The linearity in the matrix has been evaluated in the range 2–150 µg·kg⁻¹ (2, 10, 33, 100 and 150 µg·kg⁻¹). The matrix-matched solutions were prepared by adding the analytes immediately prior to LC injection. The curves were constructed, including at zero (blank), and by plotting the average peak area of analyte (three injections for each concentration point) against its concentration. An unweighted linear regression model was applied to the calibration data. The precision (repeatability and within-laboratory reproducibility), recovery (trueness), decision limit (CCₐ), and detection capability (CC₇) were studied following the experimental plans, described in Table S1 (muscle) and Table S2 (milk) of the Supplementary Material. A blank bovine muscle or milk was spiked at the beginning of the extraction procedure with the appropriate standard solutions. Four replicates (n = 4) at each level were carried out on the same day, along with the relevant matrix-matched calibration curve. Each series was repeated on three different days, and at varying times, operator, and calibration status of the LC-MS system. The spiking levels in muscles were; 10, 33, 100, 333, 1000, and 1500 µg·kg⁻¹ and 10, 33, 100, 150, and 333 µg·kg⁻¹ in milk. In milk, penicillin G, amoxicillin, and ampicillin were also tested at 2 µg·kg⁻¹. The Limits of Detection (LODs) and Quantification (LOQs) were estimated on the basis of the observed accuracy (recovery and precision) at the first validation concentration or, if necessary, at the second one.

4. Conclusions

The validity of the transfer, from LC-Q-Orbitrap to LC-QqQ of two multiclass methods for veterinary drugs in food, has been demonstrated. Using the LR platform, valnemulin in muscle, cefacetrile, and tulathromycin marker in milk did not reach acceptable precision. In addition, examining LC-QqQ results, a series of accidental events (co-elution, selected precursor ions, fragmentation pathway
etc) produced an over-estimation of cefquinome in meat, due to the co-presence of sulfamerazine. If neglected, this phenomenon could give false positive results. Since the quantification process of the LC-Q-Orbitrap system was based on a different principle (peak area of the precursor ion measured with MS accuracy < 5 ppm), this drawback was not observed. However, in milk, LC-Q-Orbitrap achieved worse recoveries for some of the more non-polar analytes, eluting in the chromatographic zone in which the interfering substances were more abundant. The “post interface ion suppression”, which is a specific phenomenon of Orbitrap mass analysers could explain this latter evidence. A further consideration concerns the chromatographic separation, which is fundamental when highly selective detectors are applied. A good separation of peaks, avoiding the overlapping and bunching of both analytes and endogenous substances, minimizes the risk of false positive results and reduces matrix effects. Finally, the described method transfer has been successfully performed on an obsolete LC-QqQ platform (fifteen year-old), encouraging the implementation of multiclass strategy also in routine laboratories with limited instrumental resources.

Supplementary Materials: The following are available online, Figure S1: LC-QqQ chromatograms of the three more polar analytes (sulfanilamide, sulfaguanidine and florfenicolamine) with different % MeOH at the beginning of the gradient: 2% (left) and 5% (right), Figure S2: Matrix-matched calibration curves of danofloxacin, doxycycline, oxacillin, spiramycin, sulfamethazine and tiamulin in meat, Figure S3: Matrix-matched calibration curves of of danofloxacin, doxycycline, oxacillin, spiramycin, sulfamethazine and tiamulin in milk, Figure S4: LC-QqQ chromatograms of a blank (a) and a milk sample spiked at 2 µg kg\(^{-1}\) (b) of the three penicillins with MRL at 4 µg kg\(^{-1}\), Figure S5: Recovery differences between the LC-QqQ and LC-Q-Orbitrap methods in meat. Positive values (%) indicate better recovery of LC-QqQ procedure and vice versa, Figure S6: LC-QqQ chromatograms of individual solutions (50 ng mL\(^{-1}\)) of sulfamerazine (left) and cefquinome (right), Figure S7: Recovery differences between the LC-QqQ and LC-Q-Orbitrap methods in bovine milk. Positive values (%) indicate better recovery of LC-QqQ procedure and vice versa, Figure S8: Precision differences between the LC-QqQ and LC-Q-Orbitrap methods in bovine milk. Positive values (%) indicate better precision of LC-QqQ procedure and vice versa, Figure S9: Precision differences between the LC-QqQ and LC-Q-Orbitrap methods in bovine milk. Positive values (%) indicate better precision of LC-QqQ procedure and vice versa, Table S1: Validation plan in bovine muscle, Table S2: Validation plan in milk, Table S3: Linearity studies in matrix (matrix-matched curves), Table S4: Calibration data (matrix-matched curves) of six representative analytes, Table S5: MRL (µg kg\(^{-1}\)), decision limits (µg kg\(^{-1}\)) and detection capabilities (µg kg\(^{-1}\)) of the 64 tested antibiotics in the main food-producing species, Table S6: MRL (µg kg\(^{-1}\)), decision limits (µg kg\(^{-1}\)) and detection capabilities (µg kg\(^{-1}\)) of the 64 antibiotics in aquaculture, rabbits, horses, Table S7: Estimated LODs and LOQs based on the observed accuracy at the first and at the second validation level.

Author Contributions: Conceptualization, D.G., S.M., G.S. and F.P.; methodology, G.S. and S.M.; validation, D.G., R.G.; preparation, R.G.; writing—review and editing, R.G., R.S. and F.I.; supervision and funding acquisition, R.G.

Funding: This research was supported by Ministero della Salute, Ricerca Corrente IZSUM 002 2015

Conflicts of Interest: The authors declare no conflict of interest.

References

1. European Communities Commission Regulation (EU) No 37/2010 of 22 December 2009 on pharmacologically active substances and their classification regarding maximum residue limits in foodstuffs of animal origin. Off. J. Eur. Communities 2010, L15, 1–72. Available online: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32010R0037 (accessed on 30 May 2019).
2. Masiá, A.; Suarez-Varela, M.M.; Llopos-Gonzalez, A.; Picó, Y. Determination of pesticides and veterinary drug residues in food by liquid chromatography-mass spectrometry: A review. Anal. Chim. Acta 2016, 936, 40–61. [CrossRef] [PubMed]
3. Mainero Rocca, L.; Gentili, A.; Pérez-Fernández, V.; Tomai, P. Veterinary drugs residues: A review of the latest analytical research on sample preparation and LC-MS based methods. Food Addit. Contam. - Part A Chem. Anal. Control. Expo. Risk Assess. 2017, 34, 766–784. [CrossRef] [PubMed]
4. Rossi, R.; Saluti, G.; Moretti, S.; Diamanti, I.; Giusepponi, D.; Galarini, R. Multiclass methods for the analysis of antibiotic residues in milk by liquid chromatography coupled to mass spectrometry: A review. Food Addit. Contam. - Part A Chem. Anal. Control. Expo. Risk Assess. 2018, 35, 241–257. [CrossRef] [PubMed]
5. Aguilera-Luiz, M.M.; Vidal, J.L.M.; Romero-González, R.; Frenich, A.G. Multi-residue determination of veterinary drugs in milk by ultra-high-pressure liquid chromatography-tandem mass spectrometry. J. Chromatogr. A 2008, 1205, 10–16. [CrossRef] [PubMed]

6. Chico, J.; Rubíes, A.; Centrich, F.; Companyó, R.; Prat, M.D.; Granados, M. High-throughput multiclass method for antibiotic residue analysis by liquid chromatography-tandem mass spectrometry. J. Chromatogr. A 2008, 1213, 189–199. [CrossRef] [PubMed]

7. Kaufmann, A.; Butcher, P.; Maden, K.; Widmer, M. Quantitative multiresidue method for about 100 veterinary drugs in different meat matrices by sub 2-microm particulate high-performance liquid chromatography coupled to time of flight mass spectrometry. J. Chromatogr. A 2008, 1194, 66–79. [CrossRef] [PubMed]

8. Stolker, A.A.M.; Rutgers, P.; Oosterink, E.; Lasaroms, J.J.P.; Peters, R.J.B.; Van Rhijn, J.A.; Nielen, M.W.F. Comprehensive screening and quantification of veterinary drugs in milk using UPLC-ToF-MS. Anal. Bioanal. Chem. 2008, 391, 2309–2322. [CrossRef]

9. Peters, R.J.B.B.; Bolck, Y.J.C.C.; Rutgers, P.; Stolker, A.A.M.M.; Nielen, M.W.F.F. Multi-residue screening of veterinary drugs in eggs, fish and meat using high-resolution liquid chromatography accurate mass time-of-flight mass spectrometry. J. Chromatogr. A 2009, 1216, 8206–8216. [CrossRef]

10. Stubbings, G.; Bigwood, T. The development and validation of a multiclass liquid chromatography tandem mass spectrometry (LC-MS/MS) procedure for the determination of veterinary drug residues in animal tissue using a QuEChERS (QUick, Easy, CHEap, Effective, Rugged and Safe) approach. Anal. Chim. Acta 2009, 637, 68–78. [CrossRef]

11. Gaugain-Juhel, M.; Delépine, B.; Gautier, S.; Fourmond, M.P.; Gaudin, V.; Hurtaud-Pessl, D.; Verdon, E.; Sanders, P. Validation of a liquid chromatography-tandem mass spectrometry screening method to monitor 58 antibiotics in milk: A qualitative approach. Food Addit. Contam. - Part A Chem. Anal. Control. Expo. Risk Assess. 2009, 26, 1459–1471. [CrossRef] [PubMed]

12. Martínez Vidal, J.L.; Frenich, A.G.; Aguilera-Luiz, M.M.; Romero-González, R. Development of fast screening methods for the analysis of veterinary drug residues in milk by liquid chromatography-triple quadrupole mass spectrometry. Analytical and Bioanalytical Chemistry. 2010, 397, 2777–2790. [CrossRef] [PubMed]

13. Kaufmann, A.; Butcher, P.; Maden, K.; Walker, S.; Widmer, M. Development of an improved high resolution mass spectrometry based multi-residue method for veterinary drugs in various food matrices. Anal. Chim. Acta 2011, 700, 86–94. [CrossRef] [PubMed]

14. Hurtaud-Pessl, D.; Jagadeshwar-Reddy, T.; Verdon, E. Development of a new screening method for the detection of antibiotic residues in muscle tissues using liquid chromatography and high resolution mass spectrometry with a LC-LTQ-Orbitrap instrument. Food Addit. Contam. - Part A Chem. Anal. Control. Expo. Risk Assess. 2011, 28, 1340–1351. [CrossRef] [PubMed]

15. Wang, J.; Leung, D. The challenges of developing a generic extraction procedure to analyze multi-class veterinary drug residues in milk and honey using ultra-high pressure liquid chromatography quadrupole time-of-flight mass spectrometry. Drug Test. Anal. 2012, 1, 103–111. [CrossRef] [PubMed]

16. Bittencourt, M.S.; Martins, M.T.; de Albuquerque, F.G.S.; Barreto, F.; Hoff, R. High-throughput multiclass screening method for antibiotic residue analysis in meat using liquid chromatography-tandem mass spectrometry: A novel minimum sample preparation procedure. Food Addit. Contam. - Part A Chem. Anal. Control. Expo. Risk Assess. 2012, 29, 508–516. [CrossRef] [PubMed]

17. Martins, M.T.; Melo, J.; Barreto, F.; Barcellos Hoff, R.; Jank, L.; Soares Bittencourt, M.; Bazzan Arsand, J.; Scherman Schapoval, E.E. A simple, fast and cheap non-SPE screening method for antibacterial residue analysis in milk and liver using liquid chromatography-tandem mass spectrometry. Talanta 2014, 129, 374–383. [CrossRef] [PubMed]

18. Kaufmann, A.; Butcher, P.; Maden, K.; Walker, S.; Widmer, M. Multi-residue quantification of veterinary drugs in milk with a novel extraction and cleanup technique: Salting out supported liquid extraction (SOSLE). Anal. Chim. Acta 2014, 820, 56–68. [CrossRef]

19. Freitas, A.; Barbosa, J.; Ramos, F. Multidetection of antibiotics in liver tissue by ultra-high-pressure-liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2015, 976–977, 49–54. [CrossRef]

20. Martins, M.T.; Barreto, F.; Hoff, R.B.; Jank, L.; Arsand, J.B.; Feijó, T.C.; Schapoval, E.E.S. Determination of quinolones and fluoroquinolones, tetracyclines and sulfonamides in bovine, swine and poultry liver using LC-MS/MS. Food Addit. Contam. - Part A Chem. Anal. Control. Expo. Risk Assess. 2015, 32, 333–341. [CrossRef]
21. Wang, J.; Leung, D.; Chow, W.; Chang, J.; Wong, J.W. Development and Validation of a Multiclass Method for Analysis of Veterinary Drug Residues in Milk Using Ultra-high Performance Liquid Chromatography Electrospray Ionization Quadrupole Orbitrap Mass Spectrometry. *J. Agric. Food Chem.* 2015, 63, 9175–9187. [CrossRef] [PubMed]

22. Dasenaki, M.E.; Thomaidis, N.S. Multi-residue determination of 115 veterinary drugs and pharmaceutical residues in milk powder, butter, fish tissue and eggs using liquid chromatography–tandem mass spectrometry. *Anal. Chim. Acta* 2015, 880, 103–121. [CrossRef] [PubMed]

23. Dasenaki, M.E.; Michali, C.S.; Thomaidis, N.S. Analysis of 76 veterinary pharmaceuticals from 13 classes including aminoglycosides in bovine muscle by hydrophilic interaction liquid chromatography–tandem mass spectrometry. *J. Chromatogr. A* 2016, 1452, 67–80. [CrossRef] [PubMed]

24. Moretti, S.; Dusi, G.; Giusepponi, D.; Pellicciotti, S.; Rossi, R.; Saluti, G.; Cruciani, G.; Galarini, R. Screening and confirmatory method for multiclass determination of 62 antibiotics in milk. *J. Chromatogr. A* 2016, 1429, 175–188. [CrossRef] [PubMed]

25. Moretti, S.; Cruciani, G.; Romanelli, S.; Rossi, R.; Saluti, G.; Galarini, R. Multiclass method for the determination of 62 antibiotics in milk. *J. Mass Spectrom.* 2016, 51, 792–804. [CrossRef] [PubMed]

26. Anumol, T.; Lehotay, S.J.; Stevens, J.; Zweigenbaum, J. Comparison of veterinary drug residue results in animal tissues by ultra-high-performance liquid chromatography coupled to triple quadrupole or quadrupole–time-of-flight tandem mass spectrometry after different sample preparation methods, including use of. *Anal. Bioanal. Chem.* 2017, 409, 2639–2653. [CrossRef] [PubMed]

27. Lehotay, S.J.; Lightfield, A.R. Simultaneous analysis of aminoglycosides with many other classes of drug residues in bovine tissues by ultra-high-performance liquid chromatography–tandem mass spectrometry using an ion-pairing reagent added to final extracts. *Anal. Bioanal. Chem.* 2018, 410, 1095–1109. [CrossRef]

28. Gaspar, A.F.; Santos, L.; Rosa, J.; Leston, S.; Barbosa, J.; Vila Pouca, A.S.; Freitas, A.; Ramos, F. Development and validation of a multi-residue and multi-class screening method of 44 antibiotics in salmon (Salmo salar) using ultra-high-performance liquid chromatography/time-of-flight mass spectrometry: Application to farmed salmon. *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.* 2019, 1118–1119, 78–84. [CrossRef]

29. Romero-González, R.; Aguilera-Luiz, M.M.; Plaza-Bolaños, P.; Frenich, A.G.; Vidal, J.L.M. Food contaminant analysis at high resolution mass spectrometry: Application for the determination of veterinary drugs in milk. *J. Chromatogr. A* 2011, 1218, 9353–9365. [CrossRef] [PubMed]

30. Commission Decision (2002/657/EC) of 12 August 2002 implementing Council Directive 96/23/EC concerning the performance of analytical methods and the interpretation of results. *Off. J. Eur. Communities* 2002, L221, 8–36.

31. Dickson, L.C. Performance characterization of a quantitative liquid chromatography-tandem mass spectrometric method for 12 macrolide and lincomamide antibiotics in salmon, shrimp and tilapia. *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.* 2014, 967, 203–210. [CrossRef] [PubMed]

32. SANCO/2004/2726-rev 4-December 2008 Guidelines for the Implementation of Decision 2002/657/EC. European Commission Health & Consumer Protection Directorate-General. 2008. Available online: https://ec.europa.eu/food/sites/food/files/safety/docs/cs_vet-med-residues_cons_2004-2726rev4_en.pdf (accessed on 30 May 2019).

33. SANTE/11813/2017. Guidance document on analytical quality control and validation procedures for pesticide residues analysis in food and feed. In European Commission Health & Consumer Protection Directorate-General. 2017. Available online: https://ec.europa.eu/food/sites/food/files/plant/docs/pesticides_mrl_guidelines_wrkdoc_2017-11813.pdf (accessed on 30 May 2019).

34. Barvick, V.J.; Willson, S.R.L. Part (d): Protocol for uncertainty evaluation from validation data. In *VAM Project 3.2.1. Development and Harmonisation of Measurement Uncertainty Principles*; LGC: Teddington, UK, 2000.

35. European Communities Commission Regulation (EU) No 37/2010 of 22 December 2009 on pharmacologically active substances and their classification regarding maximum residue limits in foodstuffs of animal origin. Consolidated test. 3 March 2019. Available online: https://eur-lex.europa.eu/collection/eu-law/consleg.html (accessed on 30 May 2019).

36. Galarini, R.; Moretti, S.; Saluti, G. Quality Assurance and Validation General Considerations and Trends. In *Chromatographic Analysis of the Environment Mass Spectrometry Based Approaches, Fourth Edition*; Leo, M.L., Nollet, D.A.L., Eds.; CRC Press: Boca Raton, FL, USA, 2017; ISBN 9781315316208.
37. Grujic, S.; Vasiljevic, T.; Lausevic, M.; Ast, T. Study on the formation of an amoxicillin adduct with methanol using electrospray ion trap tandem mass spectrometry. *Rapid Commun. Mass Spectrom.* 2008, 22, 67–74. [CrossRef] [PubMed]

38. Mastovska, K.; Lightfield, A.R. Streamlining methodology for the multiresidue analysis of beta-lactam antibiotics in bovine kidney using liquid chromatography-tandem mass spectrometry. *J. Chromatogr. A* 2008, 1202, 118–123. [CrossRef] [PubMed]

39. Asteggiante, L.G.; Nunez, A.; Lehotay, S.J.; Lightfield, A.R. Structural characterization of product ions by electrospray ionization and quadrupole time-of-flight mass spectrometry to support regulatory analysis of veterinary drug residues in foods. *Rapid Commun. Mass Spectrom.* 2014, 28, 1061–1081. [CrossRef] [PubMed]

40. Niessen, W.M.A.; Correa, R.A.C. *Interpretation of MS-MS Mass Spectra of Drugs and Pesticides*; John Wiley and Sons: Hoboken, NJ, USA, 2017.

41. Kaufmann, A.; Walker, S. Extension of the Q Orbitrap intrascan dynamic range by using a dedicated customized scan. *Rapid. Commun. Mass Spectrom.* 2016, 30, 1087–1095. [CrossRef] [PubMed]

42. *General requirements for the competence of testing and calibration laboratories*, Second ed.; International Standard Organization: Geneva, Switzerland, 2005.

43. Berendsen, B.J.A.A.; Elbers, I.J.W.W.; Stolker, A.A.M.M. Determination of the stability of antibiotics in matrix and reference solutions using a straightforward procedure applying mass spectrometric detection. *Food Addit. Contam. - Part A Chem. Anal. Control. Expo. Risk Assess.* 2011, 28, 1657–1666. [CrossRef]

44. Gaugain, M.; Chotard, M.P.; Verdon, E. Stability study for 53 antibiotics in solution and in fortified biological matrixes by LC/MS/MS. *J. AOAC Int.* 2013, 96, 471–480. [CrossRef]

**Sample Availability:** Not available.

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).